SAN DIEGO, June 19, 2018 /PRNewswire/ -- Recros Medica, Inc., an aesthetic medical device company focused on developing devicesto reduce skin laxity and improve focal contouring through its Rotational Fractional Resection platform technology, announced today that the US Patent and Trademark Office has issued a new patent for a system that includes an array of circular cutting
"Fractional resection of skin may enable the development of novel approaches to autologous skin transfer for purposes that can serve both aesthetic and therapeutic applications; providing sufficient quantities of a patient's own skin tissue, without resulting in visible scarring," stated Edward Knowlton, MD, board-certified plastic surgeon and founder of Recros Medica.
"Skin laxity becomes prevalent as people age, representing a significant unmet need as existing treatment modalities may provide only modest benefit, even with multiple treatments over several months. Rotational fractional resection may offer noticeable improvement in days with a single treatment, which could create patient demand for these treatments," stated Tom Albright, President and CEO of Recros Medica.
About Recros Medica, Inc.
Recros Medica was founded in 2014 by Dr. Edward Knowlton, a board-certified plastic surgeon who invented and founded Thermage and Viveve. Dr. Knowlton's newest invention, Rotational Fractional Resection, is a platform technology for use by dermatologists, plastic surgeons and other aesthetic physicians that can reduce skin laxity and enhance focal aesthetic contouring.
View original content:http://www.prnewswire.com/news-releases/recros-medica-announces-new-patent-issued-by-uspto-300668226.html
SOURCE Recros Medica
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All